Comparison of 30% Metformin and 2% Nicotinamide Lotion With Kligman Formula in the Treatment of Melasma

Status

Completed

Phases

Phase 2

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT05790577

Enrollment

Registered

2023-03-30

Start date

2022-02-01

Completion date

2023-02-15

Last updated

2023-05-23

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Melasma

Brief summary

Comparison of 30% Metformin and 2% Nicotinamide lotion with kligman formula in the treatment of Melasma

Detailed description

A comparative study to evaluate Efficacy and tolerability of new lotion in the treatment of Melasma.

Interventions

DRUGMetformin and Nicotinamide vs Kligman Formula

Comparison of 30% Metformin and 2% Nicotinamide lotion with kligman formula in the treatment of Melasma

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

SINGLE (Subject)

Eligibility

Sex/Gender

ALL

Age

18 Years to 50 Years

Healthy volunteers

Yes

Inclusion criteria

* Age between 18-50 * No systemic therapy * All Co-morbids

Exclusion criteria

* Pregnancy * Age \>50 * Taking oral treatment for melasma

Design outcomes

Primary

Measure	Time frame	Description
Comparison of 30% Metformin and 2% Nicotinamide lotion with kligman formula in the treatment of Melasma	12 weeks	Efficacy with measurement of MASI score 4 weeks apart

Countries

Pakistan

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026